SeQuent Scientific Restricted (SeQuent) right this moment introduced the European Union Good Manufacturing Practices (EUGMP) approval of its tablets dosage manufacturing line in Turkey.
The approval was additional complimented by the profitable renewal of EUGMP license for 8 different manufacturing strains for varied dosage kinds together with beta-lactam, non-beta lactam, terminal sterilization, mastitis, powder beta-lactam, aerosol, pesticide, and solids in Turkey.
Along with the EUGMP, the manufacturing strains in Turkey additionally maintain GMP certificates from Turkish, Saudi, Ethiopian and Sudanese authorities. With these approvals, Alivira now has a number of EUGMP accepted amenities globally, permitting it to raised serve the wants of its clients within the regulated markets of Europe, and entry to various manufacturing websites to make sure provide of top of the range merchandise.
With over 120 product registrations, SeQuent is the third-largest participant within the Turkish ruminant market with a consolidated market share of about 10%, working via its 100% subsidiaries of Provet and Topkim. The corporate has already embarked upon vital growth in Turkey to fulfill the rising necessities of the native market together with leveraging the websites for European and different strategic markets.
The announcement was made after market hours yesterday, 14 July 2021. Shares of SeQuent Scientific shed 0.54% to settle at Rs 267.80 yesterday.
SeQuent Scientific operates within the domains of Animal Well being (Alivira) and Analytical Companies. SeQuent has eight manufacturing amenities primarily based in India, Spain, Germany, Brazil and Turkey with approvals from international regulatory our bodies together with USFDA, EUGMP, WHO, TGA amongst others. Its Vizag facility is India’s first and solely USFDA accepted facility for veterinary APIs.
Powered by Capital Market – Reside Information
(This story has not been edited by Enterprise Normal workers and is auto-generated from a syndicated feed.)